Advanced and Metastatic Colorectal Cancer — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to adversely affect the prognosis of CRC in men. About a quarter of a contributor to genetic predisposition. The development time of CRC usually lasts from several to several years; therefore, diagnosing it early in developing the disease is essential. Previously diagnosed with cancer, a history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy may lead to colorectal cancer (CRC). Surgery is the primary form of treatment for colon cancer, whereas chemotherapy is typically used as an adjuvant. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%. Clinical outcomes in mCRC have improved significantly, mainly due to the identification of molecular subtypes. The median overall survival (OS) now approximates 30 months in clinical trial populations and two years in the general population. Molecular profiling of tumors is now routinely performed to identify the approximately 40% that are RAS wild type (WT) that are susceptible to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAB) therapy.
· The incidence of colorectal cancer (CRC) in the USA ranges from 40 to 45 cases per million population.
Thelansis’s “Advanced and Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced and Metastatic Colorectal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced and Metastatic Colorectal Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
